Status In progress
Process STA
ID number 446

Provisional Schedule

Committee meeting: 1 21 March 2018

Project Team

Project lead Stephanie Yates

Email enquiries

Consultees

Companies sponsors Teva Pharma B.V. (arsenic trioxide)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Bloodwise
  Leukaemia CARE
Professional groups Association of Cancer Physicians
  British Society for Haematology
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Associated public health groups None
Comparator companies Accord Healthcare Limited (cytarabine, doxorubicin, epirubicin, idarubicin) (Confidentiality agreement not signed, not participating)
  Cheplapharm Arzneimittel GmbH (tretinoin; all-trans-retinoic acid/ATRA) (Confidentiality agreement not signed, not participating)
  Hospira UK Ltd (cytarabine, epirubicin) (Confidentiality agreement not signed, not participating)
  Janssen-Cilag Ltd (doxorubicin)
  Medac GmbH (doxorubicin, epirubicin) (Confidentiality agreement not signed, not participating)
  Napp Pharmaceuticals Limited (cytarabine) (Confidentiality agreement not signed, not participating)
  Pfizer Limited (cytarabine, doxorubicin, epirubicin, idarubicin) (Confidentiality agreement not signed, not participating)
  Seacross Pharmaceuticals Ltd (doxorubicin) (Confidentiality agreement not signed, not participating)
  Teva Pharma B.V. (doxorubicin) (Confidentiality agreement not signed, not participating)
  Zentiva (daunorubicin) (Confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Institute of Cancer Research
  National Cancer Research Institute (NCRI)
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
21 December 2017 In progress, In progress
12 October 2017 Invitation to participate
27 July 2017 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance